UAE Becomes Second Country to Launch Oral GLP-1 Weight Loss Pill Nationwide
The United Arab Emirates has become one of the first countries in the world to roll out an oral GLP-1 weight loss pill nationwide, marking a major breakthrough in obesity treatment and healthcare innovation.
The medication, known as Foundayo (orforglipron), is a once-daily tablet developed by Eli Lilly. It works by mimicking natural hormones that regulate appetite and blood sugar levels, helping patients manage weight more effectively.
Unlike traditional GLP-1 treatments that require injections, this pill offers a needle-free alternative, making it easier for patients to adopt and maintain treatment. It can be taken once daily without strict timing around meals, improving convenience and accessibility.
The approval by the Emirates Drug Establishment places the UAE among the earliest adopters of this next-generation therapy, reinforcing its position as a leader in advanced healthcare solutions.
Clinical studies have shown that patients taking the drug can achieve around 12% weight loss on average, along with improvements in key health indicators such as blood pressure, cholesterol, and waist circumference.
Health experts say the introduction of oral GLP-1 medications could significantly expand access to obesity treatment, particularly for individuals hesitant to use injectable therapies. The nationwide rollout is expected to benefit thousands of patients while supporting the UAEās broader strategy to combat rising obesity rates.
However, questions remain around pricing, insurance coverage, and long-term accessibility, as authorities continue to evaluate the broader impact during the early stages of deployment.
Related News
